Tunlametinib Wins Approval in China for NRAS+ Advanced Melanoma After PD-1/PD-L1 Therapy
China’s NMPA has approved tunlametinib for the treatment of patients with NRAS-mutated advanced melanoma after prior anti–PD-1/PD-L1 therapy.
China’s NMPA has approved tunlametinib for the treatment of patients with NRAS-mutated advanced melanoma after prior anti–PD-1/PD-L1 therapy.
Join our expert faculty to delve into the management of common skin conditions in skin of color including atopic dermatitis and hyperpigmentation. They’ll explore the…
It is a glorious time of year. Spring has arrived, and the flowers are blooming. The trees are greening up again. The air is fresh…
Create a non-member account if you are applying for membership or need to interact with AAD systems. Non-member accounts do not have access to the…
A poster from the 2024 American Psychiatric Association Annual Meeting delved into the relationship between MDD and various dermatologic conditions.
This case series describes a constellation of novel adverse reactions in 3 of 9 patients with uveal melanoma receiving treatment targeting activity of the Brahma-associated…
Responding to JAAD Case Reports articles indicating a growing problem
The prevalence of gastroesophageal reflux disease (GERD) in the United States continues to increase, and up to half of patients with reflux symptoms do not…
Create a non-member account if you are applying for membership or need to interact with AAD systems. Non-member accounts do not have access to the…
This Skin Cancer Awareness Month, we have compiled a list of resources for clinicians to share with their patients.
In this episode of DermwireTV, the FDA approves a high-concentration Humira biosimilar; a study finds trifarotene combined with a skincare regimen was effective for acne-induced…